InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,348.00
(
0.43%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.83
(
0.49%
)
Bitcoin
61,493.98
(
-0.19%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ghmm

Send PM Follow Ignore
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

ghmm

Re: DewDiligence post# 214921

Tuesday, 11/07/2017 5:58:07 PM

Tuesday, November 07, 2017 5:58:07 PM

Post# of 252412
BMY / CTMX:

Don't know if this is news but apparently there is a second CTLA-4 program in the collaboration

http://ir.cytomx.com/phoenix.zhtml?c=254195&p=irol-newsArticle&ID=2315188


Bristol-Myers Squibb (BMS) Partnership

. BMS continues to advance its CTLA-4-directed Probody therapeutic, which is expected to enter the clinic in early 2018.
. In addition, CytomX and Bristol-Myers Squibb are evaluating a Probody version of Bristol-Myers Squibb's CTLA-4 nonfucosylated (CLTA-4-NF) version of ipilimumab as part of the current collaboration.



Had to google nonfucosylated never heard that before!


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up